Neuronetics (STIM) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$155.1M

Revenue (quarter)

$41.6M

Revenue growth (year over year)

+9.08%

Gross profit (trailing twelve months)

$76.2M

Gross margin

49.12%

Net income (trailing twelve months)

−$30.9M

Net income (quarter)

−$3.5M

Net income growth (year over year)

+64.79%

Net margin

−19.89%

Return on equity

−135.26%

EPS (trailing twelve months)

−$0.43

Book value per share

$0.23

P/E (trailing twelve months)

—

Price to book

6.74

Debt to assets

83.55%

Payout ratio

—

Dividend yield

—

Company profile

Neuronetics Inc a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advance Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advance Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address the existing treatment options. The company operates in two segments: medical devices and clinic services.

• Is Neuronetics (STIM) profitable?

  No. Neuronetics reported a net loss of $30.9M over the trailing twelve months.

• How much revenue does Neuronetics (STIM) make?

  Neuronetics generated $155.1M in revenue over the trailing twelve months, up 9.08% year over year.

• How do I buy stock in Neuronetics (STIM)?

  STIM trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.